Gadolinium
  
Side effects 
	
		
Options: 
			
			Show MedDRA Preferred Terms
		
	
	
| Side effect | Data for drug | Placebo | Labels | 
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 
| Discomfort | 26.4% |  |  |  |  | x |  | x | x | 
| Dysgeusia | 0.4% - 6.2% |  | x | x | x | x | x | x | x | 
| Dizziness | 0.5% - 3.74% |  | x |  | x | x | x | x | x | 
| Paraesthesia | 0.1% - 2.22% |  | x | x | x | x | x | x | x | 
| Diarrhoea | postmarketing, 1.91% |  |  |  |  |  | x | x | x | 
| Asthenia | 1.53% |  |  |  |  |  |  |  | x | 
| Rhinitis | postmarketing, 1.53% |  |  |  |  | x |  |  | x | 
| Headache | 0.5% - 9.4% |  | x | x | x | x | x | x | x | 
| Nausea | 0.6% - 3.21% |  | x | x | x | x | x | x | x | 
| Back pain | 0.6% - 1.22% |  |  |  |  | x |  |  | x | 
| Dyspepsia | 1.22% |  |  |  |  |  |  |  | x | 
| Pain | postmarketing, 0.4% - 1.83% |  |  |  |  | x |  | x | x | 
| Body temperature increased | postmarketing, 0.9% |  |  |  |  |  | x | x | x | 
| Vomiting | 0.3% - 1.4% |  |  | x | x | x | x | x | x | 
| Injection site reaction | postmarketing, 0.3% - 1.53% |  |  | x | x | x | x | x | x | 
| Injection site pain | 0.4% |  |  |  |  |  | x |  |  | 
| Coldness | 0.4% |  |  |  |  | x |  |  |  | 
| Feeling hot | 0.4% - 0.8% |  |  | x | x | x |  | x |  | 
| Rash | 0.3% |  |  | x | x | x | x | x |  | 
| Flushing | 0.3% |  |  | x | x | x |  |  |  | 
| Dyspnoea | 0.2% |  |  | x | x | x |  | x | x | 
| Fatigue | 0.2% |  |  |  |  | x | x |  |  | 
| Pruritus | 0.2% - 0.3% |  | x | x | x | x | x | x | x | 
| Erythema | 0.2% |  |  | x | x |  |  |  |  | 
| Respiratory distress | 0.2% |  |  |  |  | x |  |  |  | 
| Injection site coldness | 0.2% |  |  |  |  |  | x |  |  | 
| Vertigo | 0.1% |  | x |  |  | x |  |  | x | 
| Dry mouth | 0.1% |  |  | x | x | x |  | x | x | 
| Chills | 0.1% |  |  |  |  | x |  | x |  | 
| Feeling abnormal | 0.1% |  |  |  |  | x |  |  |  | 
| Abdominal pain | postmarketing |  |  |  |  | x |  | x |  | 
| Anaphylactic shock | postmarketing |  | x |  |  |  |  | x |  | 
| Angioedema | postmarketing |  |  | x | x |  | x |  |  | 
| Arrhythmia | postmarketing |  |  |  |  |  | x |  | x | 
| Blister | postmarketing |  |  |  |  |  |  | x |  | 
| Bronchospasm | postmarketing |  |  | x | x |  | x |  |  | 
| Chest pain | postmarketing, 0.1% |  |  | x | x | x |  | x | x | 
| Coma | postmarketing |  |  |  |  |  | x |  |  | 
| Conjunctivitis | postmarketing |  |  | x | x | x | x |  | x | 
| Connective tissue disorder | postmarketing |  |  |  |  |  | x | x |  | 
| Muscle contracture | postmarketing |  |  |  |  |  | x |  |  | 
| Cough | postmarketing |  |  | x | x | x |  |  | x | 
| Cyanosis | postmarketing |  |  | x | x |  | x |  |  | 
| Oedema | postmarketing |  |  |  |  | x |  |  | x | 
| Extravasation | postmarketing, 0.4% |  |  |  |  | x | x | x |  | 
| Gastrointestinal disorder | postmarketing |  |  |  |  |  | x | x |  | 
| Cardiac arrest | postmarketing |  |  | x | x |  | x |  |  | 
| Cardiac disorder | postmarketing |  |  |  |  |  | x | x |  | 
| Hyperhidrosis | postmarketing, 0.9% |  |  | x | x | x | x | x |  | 
| Hypersensitivity | postmarketing, 0.2% |  | x | x | x | x | x | x | x | 
| Hypoaesthesia | postmarketing |  |  |  |  | x |  |  | x | 
| Hypotension | postmarketing |  |  | x | x | x |  |  | x | 
| Immune system disorder | postmarketing |  |  |  |  |  | x | x |  | 
| Laryngeal oedema | postmarketing |  |  | x | x |  |  |  |  | 
| Laryngospasm | postmarketing |  |  |  |  |  | x | x | x | 
| Necrosis | postmarketing |  |  |  |  |  |  | x |  | 
| Nervous system disorder | postmarketing |  |  |  |  |  | x | x |  | 
| Pallor | postmarketing |  |  | x | x | x |  |  | x | 
| Pulmonary oedema | postmarketing |  |  | x | x |  |  | x |  | 
| Convulsion | postmarketing |  |  | x | x |  | x | x |  | 
| Shock | postmarketing |  |  | x | x | x |  |  |  | 
| Salivary hypersecretion | postmarketing |  |  |  |  | x | x |  | x | 
| Sneezing | postmarketing |  |  | x | x | x |  | x |  | 
| Swelling | postmarketing |  |  |  |  |  |  | x |  | 
| Syncope | postmarketing |  |  |  |  |  | x |  | x | 
| Tachycardia | postmarketing |  |  | x | x | x | x |  | x | 
| Tremor | postmarketing |  |  |  |  | x | x | x | x | 
| Loss of consciousness | postmarketing |  |  | x | x |  |  | x |  | 
| Urticaria | postmarketing |  |  | x | x | x | x | x | x | 
| Angiopathy | postmarketing |  |  |  |  |  | x |  |  | 
| Burning sensation | postmarketing, 0.2% |  | x | x | x |  | x | x |  | 
| Agitation | postmarketing |  |  |  |  | x |  |  | x | 
| Muscular weakness | postmarketing |  |  |  |  |  | x |  |  | 
| Lacrimation increased | postmarketing |  |  |  |  |  | x |  |  | 
| Ocular hyperaemia | postmarketing |  |  |  |  |  | x | x |  | 
| Eyelid oedema | postmarketing |  |  | x | x |  | x |  |  | 
| Respiratory arrest | postmarketing |  |  | x | x |  | x |  |  | 
| Unspecified disorder of skin and subcutaneous tissue | postmarketing |  |  |  |  |  | x | x |  | 
| Malaise | postmarketing |  |  | x | x | x | x | x | x | 
| Pharyngeal oedema | postmarketing |  |  |  |  |  | x |  |  | 
| Anaphylactoid reaction | postmarketing |  | x | x | x | x | x | x |  | 
| Bradycardia | postmarketing |  |  |  |  |  | x |  |  | 
| Blood pressure increased | postmarketing, 0.4% |  |  | x | x | x |  |  |  | 
| Face oedema | postmarketing |  |  | x | x | x |  |  | x | 
| Presyncope | postmarketing |  |  |  |  |  | x |  |  | 
| Phlebitis superficial | postmarketing |  |  |  |  |  | x |  |  | 
| Oropharyngeal swelling | postmarketing |  |  | x | x |  |  |  |  | 
| Parosmia | postmarketing, 0.3% |  |  | x | x | x | x | x | x | 
| Nephrogenic systemic fibrosis | postmarketing |  | x | x | x | x |  | x |  | 
| Amblyopia |  |  |  |  |  |  |  |  | x | 
| Anorexia |  |  |  |  |  |  |  |  | x | 
| Anxiety |  |  |  |  |  |  | x |  | x | 
| Arthralgia |  |  |  |  |  |  |  |  | x | 
| Asthma |  |  |  |  |  |  |  |  | x | 
| Bundle branch block |  |  |  |  |  | x |  |  |  | 
| Neck pain |  |  |  |  |  |  |  |  | x | 
| Confusional state |  |  |  |  |  |  |  |  | x | 
| Constipation |  |  |  |  |  |  |  |  | x | 
| Dysphagia |  |  |  |  |  |  |  |  | x | 
| Depersonalisation |  |  |  |  |  |  |  |  | x | 
| Diplopia |  |  |  |  |  |  |  |  | x | 
| Dysuria |  |  |  |  |  |  |  |  | x | 
| Epistaxis |  |  |  |  |  |  |  |  | x | 
| Eructation |  |  |  |  |  |  |  |  | x | 
| Erythema multiforme |  |  |  |  |  |  |  |  | x | 
| Eye disorder |  |  |  |  |  |  |  | x |  | 
| Flatulence |  |  |  |  |  |  |  |  | x | 
| Glioma |  |  |  |  |  |  |  | x |  | 
| Hallucination |  |  |  |  |  |  |  |  | x | 
| Haemoptysis |  |  |  |  |  |  |  |  | x | 
| Hypercalcaemia |  |  |  |  |  |  |  |  | x | 
| Hyperglycaemia |  |  |  |  |  |  |  |  | x | 
| Hypertension |  |  | x |  |  |  | x |  | x | 
| Hypoglycaemia |  |  |  |  |  |  |  |  | x | 
| Hyponatraemia |  |  |  |  |  |  |  |  | x | 
| Inflammation |  |  |  |  |  |  | x |  |  | 
| Eye pruritus |  |  |  |  |  |  |  | x |  | 
| Cramps of lower extremities |  |  |  |  |  |  |  |  | x | 
| Mediastinal disorder |  |  |  |  |  |  |  | x |  | 
| Hypertonia |  |  |  |  |  |  |  |  | x | 
| Nasal congestion |  |  |  |  |  |  |  | x |  | 
| Nervousness |  |  |  |  |  |  |  |  | x | 
| Numbness |  |  |  |  |  |  |  |  | x | 
| Oliguria |  |  |  |  |  |  |  |  | x | 
| Pain in extremity |  |  |  |  |  |  | x |  |  | 
| Palpitations |  |  |  | x | x | x | x |  | x | 
| Pelvic pain |  |  |  |  |  |  |  |  | x | 
| Pharyngitis |  |  |  |  |  |  |  |  | x | 
| Hyperacusis |  |  |  |  |  |  |  |  | x | 
| Sinusitis |  |  |  |  |  |  |  |  | x | 
| Muscle spasms |  |  |  |  |  |  |  |  | x | 
| Thirst |  |  |  |  |  |  |  |  | x | 
| Thrombocytopenia |  |  |  |  |  |  |  |  | x | 
| Thrombophlebitis |  |  |  |  |  |  |  |  | x | 
| Tinnitus |  |  |  |  |  |  |  |  | x | 
| Wheezing |  |  |  |  |  |  |  | x |  | 
| Atrioventricular block first degree |  |  |  |  |  |  |  | x |  | 
| Vasospasm |  |  |  |  |  |  |  |  | x | 
| Neck stiffness |  |  |  |  |  |  |  |  | x | 
| Application site reaction |  |  |  |  |  |  |  |  | x | 
| Creatinine increased |  |  |  |  |  |  |  |  | x | 
| Swelling face |  |  |  |  |  |  |  | x |  | 
| Injection site swelling |  |  |  |  |  |  |  |  | x | 
| Tongue oedema |  |  |  |  |  |  |  | x |  | 
| Injection site inflammation |  |  |  |  |  |  |  |  | x | 
| Dry skin |  |  |  |  |  |  |  |  | x | 
| Rash macular |  |  |  |  |  |  |  |  | x | 
| Myalgia |  |  |  |  |  |  |  | x | x | 
| Increased appetite |  |  |  |  |  |  |  |  | x | 
| Lip swelling |  |  |  |  |  |  |  | x |  | 
| Pancreatitis necrotising |  |  |  |  |  |  |  | x |  | 
| Eye swelling |  |  |  |  |  |  |  | x |  | 
| Akathisia |  |  |  |  |  | x |  |  |  | 
| Warmth |  |  |  |  |  |  | x |  |  | 
| Oral discomfort |  |  |  |  |  | x |  |  |  | 
| Rash maculo-papular |  |  |  |  |  | x |  |  |  | 
| Injection site bruising |  |  | x |  |  |  |  |  |  | 
| Paraesthesia oral |  |  |  |  |  |  |  | x |  | 
| Visual disturbance |  |  |  |  |  |  |  | x |  | 
| Serum creatinine increased |  |  |  |  |  |  | x |  |  | 
| Sweating increased |  |  |  |  |  |  |  |  | x | 
| Basophilia |  |  |  |  |  |  |  | x |  | 
| Blood and lymphatic system disorders |  |  |  |  |  |  |  | x |  | 
| Venipuncture site bruise |  |  | x |  |  |  |  |  |  | 
| Myasthenia |  |  |  |  |  |  |  |  | x | 
| Oropharyngeal discomfort |  |  |  |  |  |  | x |  |  | 
| Acute kidney injury |  |  |  |  |  |  | x |  |  | 
| Somnolence |  |  |  |  |  |  | x |  | x | 
	 
 
  Indications
	Information about indications was extracted from the indications and usage sections of the labels.
	
 
	  
	  
		| Side effects: | 15 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 44 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 52 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 62 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 62 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 89 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
  
 
  
	Color scheme:
	  
	  standard – alternative
	  
	
	
|  |  | 100% | 
|  |  | 75% | 
|  |  | 50% | 
|  |  | 10% | 
|  |  | frequent (1% to 100%) | 
|  |  | infrequent (0.1% to 1%) | 
|  |  | rare (<0.1%) | 
|  |  | postmarketing | 
|  |  | 0% | 
|  |  | no frequency information | 
|  |  | not found on label |